The FDA has approved a new treatment of Invokana for diabetic chronic kidney disease (CKD), which affects one in three patients with type 2 diabetes. CKD increases the risk for serious cardiovascular events and end-stage renal disease in patiens with type 2 diabetes. The approval of Invokana meets a 20 year need for therapy to […]
Adults with type 1 diabetes who use cannabis products are more than twice as likely to develop diabetic ketoacidosis as non-cannabis users with type 1, according to a recent study. The researchers say increased appetite due to cannabis use may be a factor, along with impaired ability to manage diabetes. Read more
The FDA has approved a new treatment of the diabetes drug Invokana for diabetic kidney disease, which affects one in three patients with type 2 diabetes and increases the risk for serious cardiovascular issues and kidney failure. Read more
In addition to glycemic control, liraglutide also promotes weight loss, which can be helpful in patients with obesity and type 2 diabetes. However, development of gallstones may be a common side effect in patients that are on liraglutide for the treatment of their type 2 diabetes. Read more
The U.S. Food and Drug Administration (FDA) has approved a new medication, Rybelsus (semaglutide) oral tablets, for use in controlling blood sugar in adults with type 2 diabetes, along with diet and exercise. Rybelsus is the first medication in the glucagon-like peptide (GLP-1) receptor class that does not need to be injected to be approved […]
Nonalcoholic fatty liver disease (NAFLD) often occurs in patients with type 2 diabetes. A recent study showed that the diabetes medications liraglutide and sitagliptin, in combination with metformin, can improve intrahepatic lipid and therefore benefit NAFLD. Read more
Researchers found that metformin use was associated with a substantially lower risk for dementia among younger African-American patients with diabetes when compared with sulfonylurea, according to a recently published study. Read more
Imeglimin is the first in a new class of oral antidiabetic agents, the glimins. Imeglimin decreases hepatic glucose production, increases muscle glucose uptake, and improves pancreatic glucose-dependent insulin secretion. The drug performed well in combination with metformin in its latest trial. Read more
The results of a major study show that intensive weight management strategies and drug therapy can achieve remission of type 2 diabetes. Patients who once suffered may be able to regain their previous quality of life and reduce their risk of secondary complications later down the line. Read more
The U.S. Food and Drug Administration (FDA) has approved Victoza (liraglutide) injection for treatment of pediatric patients 10 years or older with type 2 diabetes. Victoza is the first non-insulin drug approved to treat type 2 diabetes in pediatric patients since metformin was approved for pediatric use in 2000. Victoza has been approved to treat […]
Hydroxychloroquine is an anti-inflammatory drug that is among the oldest prescribed drugs first used to treat malaria. Researchers have found it may help treat autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis (RA); now, researchers say it can also help with blood glucose management in diabetes. Read more
Scientists have reported a major breakthrough in treating type 1 diabetes: a drug that can delay the development of the disease in young people at high risk. The researchers found that 2 weeks of treatment with an experimental intravenous drug delayed development of type 1 diabetes by an average of about two years. Read more
A recent study found that metformin use was associated with impaired cognitive performance and vitamin B12 deficiency. Vitamin B12 and calcium supplements may help to reduce metformin-induced vitamin B12 deficiency, and were associated with better cognitive outcomes in older patients taking metformin. Read more
The SGLT2 inhibitors class of diabetes drugs appear to increase the risk of gangrene of the genital area, a rare but potentially fatal side effect. The FDA found 55 cases of the condition, called Fournier gangrene, in people taking three common types of SGTL2 inhibitors, between March 2013 and January 2019. Read more
Results from a new study led by the University of Edinburgh and UCL suggests men taking the medicines dutasteride or finasteride to reduce the symptoms of prostate disease may be more likely to develop type 2 diabetes. Read more
Two widely used drugs for treating an enlarged prostate may increase the risk of developing type 2 diabetes. A study examined of two similar drugs, finasteride (Proscar) and dutasteride (Avodart), in 39,000 men; the 11-year study used 16,000 men taking tamsulosin (Flomax), a different type of drug for B.P.H., as controls. Compared with those using […]
Clinical trials are really stopped early, but the phase 3 trial of “Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation” a.k.a. CREDENCE, was halted early due to demonstration of significant heart and kidney benefits for canagflozin, (Invokana, Janssen Pharmaceuticals Inc.). Read more
Many medications can potentially impact your ability to be physically active. Although most drugs do not affect exercise, several common nondiabetes medications do have potential effects on exercise, including statins, beta-blockers, diuretics, vasodilators, and blood thinners. Read more
There’s been much recent discussion about whether taking the diabetes drug metformin has health benefits for people who don’t have diabetes. Some leading experts in diabetes medicine offer their opinions and recommendations on whether or not more people should be taking metformin. Read more
Taking diabetes medication to treat type 2 diabetes may also help keep Alzheimer’s disease away. A recent study found that patients with untreated diabetes developed signs of Alzheimer’s disease 1.6 times faster than people who did not have diabetes. Read more
